+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
531686 ADVIKLA

MPS Pharma Share Price

 

 

MPS Pharma live price: ₹1.81. It opened at ₹2 vs previous close ₹2; intraday high/low: ₹2/₹2. The 50 & 200 DMA stand at ₹2.16/₹2.40.

MPS Pharma Performance

  • Today's Low
  • ₹2
  • Today's High
  • ₹2
  • 52 Week Low
  • ₹2
  • 52 Week High
  • ₹3
  • Open Price₹2
  • Previous Close₹2
  • Volume25
  • 50 DMA₹2.16
  • 100 DMA₹2.45
  • 200 DMA₹2.40

MPS Pharma Chart

Investment Returns

  • Over 1 Month + 4.62%
  • Over 3 Month + 9.7%
  • Over 6 Month + 2.26%
  • Over 1 Year -34.18%

Smart Investing Starts Here Start SIP with MPS Pharma for Steady Growth!

Invest Now

MPS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -3.4
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 4
  • P/B Ratio
  • 50.6
  • Average True Range
  • 0.06
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.16
  • RSI
  • 43.57
  • MFI
  • 35.67

MPS Pharma Financials

MPS Pharma Technicals

EMA & SMA

Current Price
₹1.81
0 (0%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹1.80
  • 50 Day
  • ₹2.20
  • 100 Day
  • ₹2.40
  • 200 Day
  • ₹2.40

Resistance and Support

1.81 Pivot Speed
  • R3 1.81
  • R2 1.81
  • R1 1.81
  • S1 1.81
  • S2 1.81
  • S3 1.81

MPS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-28 Audited Results
2026-02-02 Quarterly Results
2025-11-14 Quarterly Results
2025-09-02 A.G.M.
2025-08-12 Quarterly Results

MPS Pharma Shareholding Pattern

35.89%
37.94%
26.17%

MPS Pharma FAQs

MPS Pharma share price is ₹1 As on 20 June, 2026 | 08:46

The Market Cap of MPS Pharma is ₹3.5 Cr As on 20 June, 2026 | 08:46

The P/E ratio of MPS Pharma is -3.4 As on 20 June, 2026 | 08:46

The PB ratio of MPS Pharma is 50.6 As on 20 June, 2026 | 08:46

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23